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1070-5287 Copyright  2018 Woltea,b,c a,bSabina A. Guler and Christopher J. RyersonPurpose of review
Accurate diagnosis of interstitial lung diseases (ILDs) can be challenging, and a substantial percentage of
ILD patients remain unclassifiable even after thorough assessment by an experienced multidisciplinary team.
In this review, we summarize the recent literature on the definition, prevalence, diagnosis, treatment, and
prognosis of unclassifiable ILD, and also discuss important current issues and provide future perspectives on
the classification of ILD.
Recent findings
Approximately 12% of patients with ILD are considered unclassifiable, with large variability across previous
studies that is in part secondary to inconsistent definitions of unclassifiable ILD and other ILD subtypes. A
recent International Working Group suggested that unclassifiable ILD should be defined by the absence of
a leading diagnosis that is considered more likely than not after multidisciplinary discussion of all available
information. Clinical features and outcomes of unclassifiable ILD are intermediate between idiopathic
pulmonary fibrosis and nonidiopathic pulmonary fibrosis ILD cohorts, and choices for pharmacotherapy
should be considered on a case-by-case basis.
Summary
Recent studies have provided additional data on the clinical features and prognosis of unclassifiable ILD,
but also highlight the many uncertainties that still exist in ILD diagnosis and classification. New tools are
needed to more accurately characterize patients with unclassifiable ILD.
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Interstitial lung diseases (ILDs) are a large group of
inflammatory and fibrotic disorders that damage
the lung parenchyma [1]. Despite many similarities
in symptoms and physiology at presentation, the
underlying biology, prognosis, and recommended
treatment approaches differ substantially across ILD
subtypes [1–3]. For example, idiopathic pulmonary
fibrosis (IPF), which is characterized by a radiologi-
cal and pathological usual interstitial pneumonia
(UIP) pattern, ismore frequent in oldermen, current
or former smokers, and patients with gastroesopha-
geal reflux [3]. In contrast, connective tissue disease
(CTD)-associated ILDs occur more frequently in
younger women [4], while patients with hypersen-
sitivity pneumonitis are less likely to be smokers [5].
There are antifibrotic therapies that can slow pro-
gression of IPF [6,7], while immunosuppressive
pharmacotherapies are commonly used for non-
IPF ILDs [8,9].
Distinguishing among ILD subtypes is fre-
quently challenging, and accurate diagnosis oftenht © 2018 Wolters Kluwe
rs Kluwer Health, Inc. All rights reserequires a multidisciplinary effort by a team of expe-
rienced ILD clinicians, chest radiologists, and lung
pathologists [10
&
]. Even after a comprehensive eval-
uation by a group of experts, a substantial percent-
age of ILD patients cannot be provided with a
specific diagnosis and are labeled with ‘unclassifi-
able ILD’ [11–13]. In this review, we summarize the
evolving literature on the definition, prevalence,
diagnosis, treatment, and prognosis of unclassifiable
ILD, and we discuss potential approaches to its
phenotyping and management.r Health, Inc. All rights reserved.
rved. www.co-pulmonarymedicine.com
KEY POINTS
 A large percentage of patients with ILD are
unclassifiable, even after a comprehensive review of all
clinical, radiological, and pathological information by
a group of experts.
 Choices for pharmacotherapy of unclassifiable ILD
require a case-by-case consideration of the relative
likelihoods of the differential diagnosis, the anticipated
disease behavior and response to therapy, and
potential medication adverse effects and tolerability.
 A more precise definition, novel diagnostic tools,
guidance on how to approach specific clinical
scenarios are needed to advance our understanding of
unclassifiable ILD.
Interstitial lung diseaseDEFINITION AND TERMINOLOGY
Clinicians and researchers have used several terms
to indicate that a patient with ILD cannot be pro-
vided with a specific diagnosis, including unclassi-
fiable ILD, unclassified ILD, undefined ILD, and
undetermined ILD [11,14–16]. The most common
definition of unclassifiable ILD is the absence of a
specific diagnosis following a multidisciplinary dis-
cussion and review of available clinical, radiological,
and pathological information [11,12
&
], but the
threshold for considering an ILD patient unclassifi-
able has been inconsistently applied and is not Copyright © 2018 Wolters Kluwer 
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FIGURE 1. Proposed approach to the classification of fibrotic in
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[1,17]. An International Working Group perspective
recently suggested that unclassifiable ILD be defined
by the absence of a leading diagnosis that is consid-
ered more likely than not (i.e., no single diagnosis
that is thought to be at least 51% likely after multi-
disciplinary discussion), with a provisional and con-
fident diagnosis applying to patients with 51–89%
diagnostic confidence and at least 90% confidence,
respectively [18
&
]. This group recommended that
unclassifiable ILD be further subclassified according
to whether an adequate surgical lung biopsy was
available, and further that a differential diagnosis
should be provided and most notably whether IPF
was considered a likely possibility (Fig. 1) [18
&
].
Previous studies have described many reasons for
not being able to confidently diagnose a patient
with ILD. These can be broadly categorized into
three common scenarios, including an incomplete
evaluation, the presence of overlapping findings
that are common to multiple distinct ILD subtypes,
and nonspecific findings that are not characteristic
of any single ILD subtype. Examples for each of these
possibilities are presented in Table 1.PREVALENCE
Estimates for the prevalence of specific ILD subtypes
vary substantially. Studies on ILD epidemiology are
frequently based on International Classification ofHealth, Inc. All rights reserved.
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terstitial lung disease. Reprinted with permission [18&] of the
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Table 1. Reasons for unclassifiable interstitial lung disease
Clinical [11,12&] Radiological [19&] Pathological [20&]
Multidisciplinary
discussion [11,12&,21]
Incomplete
evaluation
Unable to obtain adequate
history (e.g., exposures)
Not available No biopsy performed (e.g.,
unfavorable risk–benefit
ratio, patient preference)
Not available
HRCT quality insufficient Insufficient biopsy quality
(too small, damaged,
nonoptimal sampling
location)
Difficult interpretation of
poor quality diagnostic
material
Overlapping
findings
Multiple risk factors
predisposing for different
specific ILDs
Overlap with non-ILD
features (e.g., cardiac
failure, infection)
Overlapping histological
features
Discrepant clinical,
radiological, and
pathological features
Acute exacerbation Discrepant interpretation of
information by members
Features of different specific
ILDs
Nonspecific
findings
Stable disease, mild
symptoms
Indeterminate for UIP Only advanced interstitial
fibrosis
Poorly classifiable findings
Prior treatment (e.g.,
corticosteroids)
Prior treatment (e.g.,
corticosteroids)
HRCT, high-resolution computed tomography; ILD, interstitial lung disease; UIP, usual interstitial pneumonia.
Unclassifiable interstitial lung disease Guler and RyersonDiseases codes that have significant limitations
compared with contemporary ILD classification
[22–24]. Other studies have been based on cohorts
recruited from ILD referral centers, and are thus not
representative of the general population. Within
these specialized ILD clinics, the prevalence of
unclassifiable ILD is estimated to be approximately
12%, but with substantial variability between stud-
ies likely due to heterogeneous study designs and
diagnostic approaches [13]. The proportion of ILD
patients who remain unclassifiable may be lower in
cohorts that have undergone a multidisciplinary
discussion [13], and is particularly high (up to
45%) in an elderly ILD population [25].CLINICAL FEATURES AND
INVESTIGATIONS
The clinical features of unclassifiable ILD are similar
to other common fibrotic ILD subtypes for twomain
reasons. First, a relatively consistent burden of dys-
pnea, cough, and functional limitation prompts
patients to seek medical attention, regardless of
the underlying cause, and thus patients have similar
ILD severity at the time of diagnosis. Second, unclas-
sifiable ILD likely includes a heterogeneous mixture
of patients, and thus consists of patients with clini-
cal features that are intermediate between the dif-
ferent diagnostic possibilities.
Symptoms of unclassifiable ILD are nonspecific,
including dyspnea, cough, chest discomfort, reduced
exercise capacity, and fatigue. Patients often have Copyright © 2018 Wolters Kluwe
1070-5287 Copyright  2018 Wolters Kluwer Health, Inc. All rights reseexertional hypoxemia that eventually can occur at
rest, crackles on lung auscultation, and occasionally
digital clubbing [12
&
]. The mean age in previous
cohorts ranges from 58 to 65 years, and about 50%
of patients have a history of cigarette smoking
[2,12
&
,26–30]. Some studies report a balanced sex
distribution [2,26], and others either a male
[12
&
,27,28], or female predominance [29
&
,30]. At diag-
nosis, patients have mild reduction in forced vital
capacity (FVC) and moderate reduction in diffusion
capacity of the lung for carbon monoxide (DLCO)
(66–79% and 41–55%, respectively) [2,12
&
,26–30].
A subgroup of patients with unclassifiable ILD have
autoimmune featuresbutcannotbeassigneda specific
CTD diagnosis, with a proposal that these patients be
labeled as having interstitial pneumoniawith autoim-
mune features [31]. Future studies are needed to dem-
onstrate the clinical validity of this grouping, and to
evaluate its potential treatment implications.
The diagnosis and classification of ILDs requires
high-quality, thin section, preferably contiguous
high-resolution computed tomography (HRCT)
imaging. Few studies report HRCT findings of
patients with unclassifiable ILD, and patterns are
either nonspecific or difficult to classify. Two studies
have reported radiological patterns of patients with
unclassifiable ILD, with definite UIP reported in 6–
17%andpossibleUIP in 26–50%of patients [11,29
&
].
Other commonly reported radiological patterns
include nonspecific interstitial pneumonia, desqua-
mative interstitial pneumonia, and features sug-
gested of chronic hypersensitivity pneumonitis [12
&
].r Health, Inc. All rights reserved.
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DEMOGRAPHICS
EXPOSURES
LABORATORY
HRCT
HISTOPATHOLOGY
Odds rao, 95% conﬁdence interval
OR 95% CI
4.6 2.9-7.6
6.4 4.3-9.8
2.77 1.8-4.5
0.03 0.01-0.09
0.31 0.2-0.5
0.2 0.1-0.4
0.19 0.1-0.37
5.46 1.37-21.8
11.5 2.97-44
8.3 1.98-60
0.34 0.18-0.63
0.28 0.1-0.78
0.12 0.02-0.82
0.04 0-0.4
0.01 0.1 1 10 100
IPFnon-IPF ILD
Favors
*Age > 60 years
*Male sex
*Smoker
1Posive precipitang anbodies
*Posive CTD serology, any
*Posive CTD serology, ANA
1Angen exposure
2Deﬁnite/Probable UIP paern
2Honeycombing
3Fibroblast score
4Germinal centers
5Organizing pneumonia
5Granulomas
5Centrilobular ﬁbrosis
FIGURE 2. Selected features that increase or decrease the odds of idiopathic pulmonary fibrosis. Data from the St. Paul’s
Hospital (Vancouver, Canada) interstitial lung disease database of 882 patients; 1. Lacasse et al. (2003) [5], 2. Hunninghake
et al. (2003) [38], 3. Flaherty et al. (2003) [39], 4. Song et al. (2009) [40], and 5. Takemura et al. (2012) [41]. 95% CI,
95% confidence interval; ANA, antinuclear antibody; CTD, connective tissue disease; ILD, interstitial lung disease; IPF,
idiopathic pulmonary fibrosis; OR, odds ratio; UIP, usual interstitial pneumonia.
Interstitial lung diseaseThe largest studies of patients with unclassifi-
able ILD report only 22–28% of patients underwent
a surgical lung biopsy [11,12
&
,29
&
], with the major-
ity of these patientshavingoverlappinghistological
patterns [29
&
]. Surgical lung biopsy was not per-
formed in the remaining patients for a variety of
reasons, largely driven by the uncertain risk–bene-
fit ratio in some situations. Specifically, the esti-
mated in-hospital mortality of 1.7% for elective
procedures and 16% for nonelective biopsies can
be difficult to justify in patients with mild and
potentially nonprogressive disease and in patients
with advanced ILD that is associated with greater
risk of complication [32
&
,33
&
]. Furthermore, surgi-
cal lung biopsy does not always yield a specific
ILD diagnosis, with approximately 10% of cases
still remaining unclassifiable following biopsy
[12
&
,34]. Consequently, the risk of biopsy should
be weighed against the potential benefit on an
individual basis including consideration of patient
preference.
Bronchoalveolar lavage cellular analysis is usu-
ally nonspecific in patients with unclassifiable ILD
[15,28]. Transbronchial lung cryobiopsy has a
higher diagnostic yield compared with conven-
tional transbronchial biopsy and might allow
pathological phenotyping in a population of unclas-
sifiable ILD patients that does not qualify for Copyright © 2018 Wolters Kluwer 
464 www.co-pulmonarymedicine.comsurgical lung biopsy [35
&
,36
&
]; however, the safety
and yield of cryobiopsy have not been clearly estab-
lished in comparisonwith surgical lung biopsy [35
&
].
Additional data are needed to clarify the role of
bronchoscopic studies in patients with fibrotic ILD.
The above features are best considered in the
context of a multidisciplinary discussion of experts,
typically defined as a dynamic face-to-face review of
all available clinical, radiological, and pathological
data. Multidisciplinary discussion has replaced the
previous pathological reference standard for ILD
diagnosis [17], and is strongly recommended in
recent guidelines for patients with fibrotic ILD
[1,3]. Multidisciplinary teams should particularly
consider the many factors that can alter the likeli-
hood of an IPF or a non-IPF ILD diagnosis (Fig. 2).
This process improves diagnostic confidence
[10
&
,37], and may decrease the percentage of
patients who are considered unclassifiable [13].MANAGEMENT
Many nonpharmacological therapies for patients
with fibrotic ILD are nonspecific and should rou-
tinely be considered for patients with unclassifiable
ILD. These include smoking cessation, avoidance of
potentially harmful exposures, pneumococcal and
influenza vaccinations, pulmonary rehabilitation,Health, Inc. All rights reserved.
Volume 24  Number 5  September 2018
Unclassifiable interstitial lung disease Guler and Ryersonlong-term oxygen therapy, and management of
comorbidities. Lung transplantation is an option
for some patients with unclassifiable ILD, while
others might benefit more from a more palliative
approach that places greater emphasis on symptom
management.
Antifibrotic medications (pirfenidone and nin-
tedanib) are only approved for the treatment of IPF,
with most regions funding these therapies exclu-
sively in patients who meet IPF diagnostic criteria
from established clinical practice guidelines [6,7].
Subgroup analyses suggest that nintedanib may be
beneficial in patients with suspected IPF who did
not meet guideline criteria [42
&
]; however, addi-
tional studies are needed to better define this sub-
group of potential responders and to replicate this
finding prospectively. Randomized controlled trials
are currently evaluating this question by testing the
safety and efficacy of pirfenidone and nintedanib in
patients with unclassifiable ILD (Table 2) [43,44].
Immunosuppressive medications may be a treat-
ment option for unclassifiable ILD when there is a
low likelihood of IPF and a primary differential
diagnosis of chronic hypersensitivity pneumonitis
[9], CTD-ILD [45], or other non-IPF ILDs [46]. The
decision to initiate a trial of immunosuppressive
therapy in this situation must be balanced against
the previously demonstrated detrimental effects
of immunosuppressive therapy in patients with
IPF [47].PROGNOSIS
The survival of patients with unclassifiable ILD
appears to be intermediate between the survival of
IPF and non-IPF ILD patients, with 2-year survival
rates ranging from 70 to 76% [11,12
&
,28,29
&
]. This is
again expected considering the heterogeneous Copyright © 2018 Wolters Kluwe
Table 2. Ongoing randomized controlled trials in patients with u
Study Patients,
n
Study design Key in
crite
Pirfenidone in patients
with unclassifiable
progressive fibrosing
ILD [43]
250 Phase II, double-blind,
randomized,
placebo-controlled
Rate of de
FVC>5
symptom
worseni
the last
Efficacy and safety of
nintedanib over
52 weeks in patients
with progressive
fibrosing interstitial
lung disease [44,48]
600 Phase III, double-blind,
randomized,
placebo-controlled
Rate of de
FVC>1
and sym
or radio
worseni
the last
months
FVC, forced vital capacity; ILD, interstitial lung disease; n, number.
1070-5287 Copyright  2018 Wolters Kluwer Health, Inc. All rights resepopulation of unclassifiable ILD that includes
patients with mild disease in which biopsy is not
considered necessary and other patients with severe
disease that prohibits performance of a surgical lung
biopsy. Independent risk factors for mortality in
patients with unclassifiable ILD include older age,
lower FVC, and crackles on lung auscultation [12
&
],
with lower DLCO%-predicted and higher fibrosis
score on HRCT independently predicting both mor-
tality and disease progression in another study [11].
Traction bronchiectasis on HRCT, increased pulmo-
nary artery diameter, and higher Composite Physi-
ologic Index have also been reported as mortality
risk factors [29
&
].DISCUSSION
Our understanding of ILD diagnosis and classifica-
tion continues to evolve. Recent publications have
provided a framework for a more consistent
approach to ILD diagnosis, and the future study of
these patients. Despite these advances, there
remain several important questions related to
unclassifiable ILD.Is unclassifiable interstitial lung disease a
useful category?
The main potential downside to designation of
unclassifiable ILD as a disease category is that it is
a heterogeneous and poorly defined collection of
patients, and that providing a label for these
patients might be used as justification to refrain
from further pursuit of an underlying cause [49].
It is critical, however, that this label should instead
prompt a regular re-evaluation and search for new
information that might increase the confidence in
a specific ILD diagnosis. It is unknown whatr Health, Inc. All rights reserved.
nclassifiable interstitial lung disease
clusion
ria
Primary
outcome
Treatment/
duration
Expected date
of results
cline in
% or
atic
ng over
6 months
Rate of decline
in FVC
Pirfenidone titrated
up to 2403mg/
day for 24 weeks
Early 2020
cline in
0 or >5%
ptomatic
logical
ng over
24
Rate of decline
in FVC
Nintedanib 150mg
twice daily for 52
weeks
Late 2019
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Interstitial lung diseasepercentage of unclassifiable ILD cases can be
assigned a confident diagnosis at re-evaluation
and how frequently cases should be revisited. The
most practical approach is to conduct this reassess-
ment on an ad hoc basis, with a likely role to
perform some tests more regularly (e.g., serologies
or computed tomography every 1–2 years). Regard-
less, there remain a large number of ILD patients
that cannot be assigned a specific diagnosis. Having
a label for these patients is necessary to facilitate
studies of these patients, including identification of
its biological and clinical phenotypes as well as
enrolment of patients in clinical trials. For clinical
purposes, the integration of available data into a
‘working diagnosis’ can facilitate pragmatic man-
agement decisions; however, it is important to rec-
ognize the need to reassess the diagnosis of these
patients during long-term follow-up.How should unclassifiable interstitial lung
disease be defined and subcategorized?
An International Working Group recently proposed
that unclassifiable ILD be defined by the absence of a
leading diagnosis that is consideredmore likely than
not (Fig. 1) [18
&
]; however, this is a highly subjective
definition that is significantly impacted by the thor-
oughness of the diagnostic evaluation. Some studies
have required a surgical lung biopsy prior to catego-
rization of an ILD patient as unclassifiable; however,
this working group instead suggested both biopsied
and nonbiopsied patients be considered in the same
category, but with subgrouping according to the
presence or absence of a biopsy. Similarly, some
studies have required a multidisciplinary discussion
for these patients; however, this resource is not
available in many regions and has other incom-
pletely understood limitations that prohibit its rou-
tine requirement in the ILD diagnostic process.
Currently, it remains unclear how unclassifiable
ILD should be defined, which diagnostic steps
should be compulsory before calling a case unclas-
sifiable, and how unclassifiable ILD should be sub-
categorized. Advances in molecular phenotyping
with transcriptomics [50,51], proteomics [52,53],
metabolomics [54,55], and epigenetics [56] may
eventually allow an accurate ILD diagnosis
in many patients who are currently considered
unclassifiable.What pharmacotherapies should be
considered for patients with unclassifiable
interstitial lung disease?
Choices for pharmacotherapy of unclassifiable
ILD are challenging and require a case-by-case Copyright © 2018 Wolters Kluwer 
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ferential diagnosis, the anticipated disease behavior
and response to therapy, and potential medication
adverse effects and tolerability. Potential treatment
options for patients with unclassifiable ILD include
short-term immunosuppressive therapy with reas-
sessment of the initial treatment response, long-
term immunosuppressive therapy, antifibrotic ther-
apy, and observation without pharmacotherapy.
Determining whether a given treatment strategy
has been effective in an individual patient is limited
by the heterogeneous disease progression. For this
reason, disease progression despite therapy is often
interpreted as a failure of therapy; however, disease
stability while on a given treatment is of less certain
significance. Given the absence of proven benefit for
any pharmacotherapy in unclassifiable ILD, obser-
vation without therapy should be considered in
patients with mild and stable disease, or in frail
patients who might be more prone to clinically
significant adverse effects.
Clinical trials are currently ongoing in unclassi-
fiable ILD; however, design of these studies and their
translation into clinical practice is amajor challenge
for several reasons. First, unclassifiable ILD is incon-
sistently defined in the previous literature, and
attempts to standardize the nomenclature and defi-
nition for this group of patients remains highly
subjective [18
&
]. Second, large patient numbers
and careful selection of trial endpoints are required
to overcome the ‘noise’ that arises from the variable
rates of progression for the heterogeneous popula-
tion of patients with unclassifiable ILD. Third, the
heterogeneous biology of unclassifiable ILD indi-
cates that targeted therapiesmay be unlikely towork
except in small and more consistently defined sub-
groups. Despite these limitations, there is much
insight to be gained from the testing of potential
pharmacological interventions in these patients,
and specifically evaluation of biological predictors
of response to therapy.CONCLUSION
Unclassifiable ILD is a common, but heterogeneous
and poorly defined subgroup of ILD. Recent studies
have provided additional data on the clinical fea-
tures and prognosis of unclassifiable ILD, but
also highlight the many uncertainties that still
exist in ILD diagnosis and classification. Novel
approaches to ILD diagnosis and classification are
needed to advance our understanding of unclassifi-
able ILD, reduce the proportion of unclassifiable
cases, and support development of evidence-
based treatment approaches for specific biological
phenotypes.Health, Inc. All rights reserved.
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